Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Virpax Pharmaceuticals, Inc. (VRPX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.3000-0.1300 (-9.09%)
At close: 03:59PM EDT
1.4500 +0.15 (+11.54%)
After hours: 04:27PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close1.4300
Open1.4500
Bid1.3000 x 800
Ask1.4500 x 800
Day's Range1.3000 - 1.4700
52 Week Range1.1900 - 21.7900
Volume169,713
Avg. Volume66,495
Market Cap15.229M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.7190
Earnings DateMay 18, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for VRPX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Virpax Pharmaceuticals, Inc.
    Daily – Vickers Top Buyers & Sellers for 08/16/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • Business Wire

    Virpax Pharmaceuticals Reports 2022 Second Quarter Results and Recent Developments

    BERWYN, Pa., August 15, 2022--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive product candidates for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the quarter ended June 30, 2022, and other recent developments.

  • American City Business Journals

    15 Philadelphia-area Black executives listed among the most influential in corporate America by Savoy

    Fifteen of the 337 executives recognized by Savoy work in the Philadelphia region, including two sets of executives who work at the same office.

  • Business Wire

    Virpax Pursues OTC Medical Device Pathway for AnQlar™

    BERWYN, Pa., July 05, 2022--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral indications, today announced it will pursue an OTC Intranasal Medical Device Consumer regulatory pathway for AnQlar™, the Company’s product candidate being developed as a prophylactic antiviral barrier against influenza and SARS-Co

Advertisement
Advertisement